gsk201307196k2.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending July 2013
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--

 


 
 


 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
I give below details of the following increases in interests in Ordinary Shares in GlaxoSmithKline plc purchased at a price of 1743.15 pence per Share on 16 July 2013, in respect of the personal holdings of the under-mentioned persons
following the re-investment of the dividend paid to shareholders on 11 July 2013.
 
 
 
   Ordinary Shares
   Sir Andrew Witty
 
   601.941
   Dr M M Slaoui
   213.376
   Mr S M Bicknell
   129.066
   Mr R G Connor
   34.944
   Mr S A Hussain
   1,018.303
   Mr D S Redfern
   308.842
   Ms C Thomas
   343.933
   Mr P C Thomson
   102.065
   Dr P J T Vallance
 
   312.179
   Ms E Walmsley
 
   136.429
   Mr C Weber
   313.184
 
 
 
The Company was advised of this information on 18 July 2013.
 
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
 
V A Whyte
Company Secretary
 
19 July 2013
 
 

 
 
 
 
 

 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: July 19,  2013
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc